Expert Ideas

Expert Ideas Recent News

AeroVironment's BlueHalo Integration Signals Next Growth Phase: Analyst
AeroVironment's BlueHalo Integration Signals Next Growth Phase: Analyst
AeroVironment's acquisition of BlueHalo strengthens its position in defense technologies. Bank of America raises price forecast to $450.
Trump Tariffs May Fuel Margin Squeeze, But Not Inflation, Economist Says
Trump Tariffs May Fuel Margin Squeeze, But Not Inflation, Economist Says
Economist Jeffrey Roach tells Benzinga Trump's tariffs won't reignite inflation, as U.S. firms absorb costs.
Lam Research Remains Top Pick Despite China Risks, Says Analyst
Lam Research Remains Top Pick Despite China Risks, Says Analyst
Lam Research (NASDAQ: LRCX) is expected to see strong growth in 2026 despite China challenges, with Bank of America naming it top pick.
Northern Cyprus' Reliance On Turkish Lira Undermines Cypriot Peace Hopes
Northern Cyprus' Reliance On Turkish Lira Undermines Cypriot Peace Hopes
T-Mobile's Subscriber Boom Isn't Enough for Wall Street, Analyst Explains Why
T-Mobile's Subscriber Boom Isn't Enough for Wall Street, Analyst Explains Why
T-Mobile (TMUS) reported strong customer growth but its financial forecast caused concern among investors. Stock down 2.65% to $221.38.
GE Vernova's Strong Orders And Prolec Deal Signal Major Growth: Analyst
GE Vernova's Strong Orders And Prolec Deal Signal Major Growth: Analyst
GEV reports strong Q3 with 55% organic order surge, plans to acquire full ownership of Prolec GE, reaffirms 2025 guidance.
How Did American Airlines Shrink Its Loss Despite Rising Costs?
How Did American Airlines Shrink Its Loss Despite Rising Costs?
AAL reported narrower Q3 loss, beat estimates and raised full year guidance. Goldman Sachs maintains a sell rating with $10 price target.
Stock Of The Day: Why Did Beyond Meat Collapse?
Stock Of The Day: Why Did Beyond Meat Collapse?
Beyond Meant (BYND) went into a short squeeze over the past few days. It may be over and the price may drop.
Why Top Analyst Still Says Buy IBM, Even As Its Cloud Business Slows
Why Top Analyst Still Says Buy IBM, Even As Its Cloud Business Slows
IBM beats Q3 expectations with strong Infrastructure and Automation divisions, raises guidance despite weaker software segments.
New Russia Sanctions Trigger A Buy Signal On Oil And Give Gold Second Wind; Government May Back Quantum Computing
New Russia Sanctions Trigger A Buy Signal On Oil And Give Gold Second Wind; Government May Back Quantum Computing
New Oil Sanctions
Lam Research Stock Gains On Solid Results, Analyst Highlights AI-Driven Outlook
Lam Research Stock Gains On Solid Results, Analyst Highlights AI-Driven Outlook
Lam Research reports strong earnings and raised guidance, but high investor expectations led to a dampened stock performance.
Every Time Jim Cramer Said 'Sell Crypto' - Here's What Happened Next
Every Time Jim Cramer Said 'Sell Crypto' - Here's What Happened Next
CNBC host Jim Cramer is once again sounding alarms about cryptocurrencies, urging investors to pull their money from digital assets and focus on stocks instead.
Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins
Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins
Medpace shares climb as Q3 earnings and revenue top estimates, driven by strong bookings, rising backlog, and an upbeat 2025 guidance.
If You Can't Explain Web3 In Two Sentences, You Don't Understand It
If You Can't Explain Web3 In Two Sentences, You Don't Understand It
Tesla Stock Has 'Limited Valuation Support': Analysts See Near-Term Risks After Q3 Results
Tesla Stock Has 'Limited Valuation Support': Analysts See Near-Term Risks After Q3 Results
Tesla analysts highlight near-term risks for the company after Q3 results, with long-term questions and opportunities weighing on shares.
Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection
Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection
Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven and financial guidance.
A Disappointing Hong Kong Debut, Yet Fibocom Still At Frothy Valuations
A Disappointing Hong Kong Debut, Yet Fibocom Still At Frothy Valuations
Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership
Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2025 Benzinga | All Rights Reserved